Means for the inhibition of anti-β1-adrenergic receptor antibodies
    1.
    发明授权
    Means for the inhibition of anti-β1-adrenergic receptor antibodies 有权
    用于抑制抗β1肾上腺素能受体抗体的方法

    公开(公告)号:US08716030B2

    公开(公告)日:2014-05-06

    申请号:US13449966

    申请日:2012-04-18

    IPC分类号: G01N33/564

    CPC分类号: C07K14/70571 C07K7/64

    摘要: Embodiments of the present invention provide for novel peptides of use for detection and/or inhibition of anti-β1-adrenergic receptor antibodies. Certain embodiments concern uses of cyclic and/or linear peptides. In other embodiments, the present invention relates to novel peptides of use in diagnostic and/or pharmaceutical compositions. Some embodiments concern diagnosing and/or treating cardiac conditions. Cardiac conditions of the instant invention can concern infectious heart disease, non-infectious heart disease, ischemic heart disease, non-ischemic heart disease, inflammatory heart disease, myocarditis, cardiac dilatation, idiopathic cardiomyopathy, idiopathic dilated cardiomyopathy, immune-cardiomyopathy, heart failure, and any cardiac arrhythmia condition.

    摘要翻译: 本发明的实施方案提供了用于检测和/或抑制抗 - 1-肾上腺素能受体抗体的新型肽。 某些实施方案涉及环肽和/或线性肽的使用。 在其它实施方案中,本发明涉及用于诊断和/或药物组合物的新型肽。 一些实施方案涉及诊断和/或治疗心脏病症。 本发明的心脏病可以涉及感染性心脏病,非传染性心脏病,缺血性心脏病,非缺血性心脏病,炎性心脏病,心肌炎,心脏扩张,特发性心肌病,特发性扩张型心肌病,免疫性心肌病,心力衰竭 ,以及任何心律失常症状。

    Means for the inhibition of anti-beta1-adrenergic receptor antibodies
    2.
    发明授权
    Means for the inhibition of anti-beta1-adrenergic receptor antibodies 有权
    用于抑制抗β1-肾上腺素能受体抗体的方法

    公开(公告)号:US08715682B2

    公开(公告)日:2014-05-06

    申请号:US13449984

    申请日:2012-04-18

    IPC分类号: A61K38/12 C07K7/52 G01N33/564

    CPC分类号: C07K14/70571 C07K7/64

    摘要: Embodiments of the present invention provide for novel peptides of use for detection and/or inhibition of anti-β1-adrenergic receptor antibodies. Certain embodiments concern uses of cyclic and/or linear peptides. In other embodiments, the present invention relates to novel peptides of use in diagnostic and/or pharmaceutical compositions. Some embodiments concern diagnosing and/or treating cardiac conditions. Cardiac conditions of the instant invention can concern infectious heart disease, non-infectious heart disease, ischemic heart disease, non-ischemic heart disease, inflammatory heart disease, myocarditis, cardiac dilatation, idiopathic cardiomyopathy, idiopathic dilated cardiomyopathy, immune-cardiomyopathy, heart failure, and any cardiac arrhythmia condition.

    摘要翻译: 本发明的实施方案提供了用于检测和/或抑制抗 - 1-肾上腺素能受体抗体的新型肽。 某些实施方案涉及环肽和/或线性肽的使用。 在其它实施方案中,本发明涉及用于诊断和/或药物组合物的新型肽。 一些实施方案涉及诊断和/或治疗心脏病症。 本发明的心脏病可以涉及感染性心脏病,非传染性心脏病,缺血性心脏病,非缺血性心脏病,炎性心脏病,心肌炎,心脏扩张,特发性心肌病,特发性扩张型心肌病,免疫性心肌病,心力衰竭 ,以及任何心律失常症状。

    Means for the inhibition of anti-beta1-adrenergic receptor antibodies
    3.
    发明申请
    Means for the inhibition of anti-beta1-adrenergic receptor antibodies 有权
    用于抑制抗β1-肾上腺素能受体抗体的方法

    公开(公告)号:US20090215675A1

    公开(公告)日:2009-08-27

    申请号:US11910258

    申请日:2006-03-31

    CPC分类号: C07K14/70571 C07K7/64

    摘要: The present invention is related to a peptide selected from the group comprising a) a cyclic peptide of formula (I): Cyclo(AIa-x-x-x-x-x-x-x-x-x-Cys-x-x-x-Pro-x-Cys-Cys-xk-GIn), (I) whereby k is any integer from 0 to 6, preferably any integer from 1 to 6, more preferably k=6; b) a cyclic peptide of formula (II): Cyclo(Ala-x-x-Trp-x-x-Gly-x-Phe-x-Cys-xh-Gln), (II) whereby h is any integer from 0 to 2, preferably 1 or 2; c) a cyclic peptide of formula (III): Cyclo(AIa-x-x-x-x-x-x-x-x-x-Cys-xj-Cys-x-x-x-Pro-x-Cys-Cys-xi-Gln); (HI) whereby j is any integer from 0 to 4, preferably j=4; whereby i is any integer from 0 to 6, preferably any integer from 1 to 6, more preferably i−6; and d) a peptide of formula (IV): Ala-x1-Cys-xm-Cys-x-x-x-Pro-x-Cys-Cys-xn-Gln, (IV) whereby 1 is any integer from 0 to 9, preferably any integer from 1 to 9, more preferably n=9; whereby m is any integer from 0 to 4, preferably any integer from 1 to 4, more preferably m=4; whereby n is any integer from O to 6, preferably any integer from 1 to 6, more preferably n=6; whereby x is any amino acid, preferably any naturally occurring amino acid, more preferably any naturally occurring L-amino acid.

    摘要翻译: 本发明涉及一种选自以下的肽:a)式(I)的环状肽:Cyclo(Ala-xxxxxxxxx-Cys-xxx-Pro-x-Cys-Cys-xk-Gln),(I) 其中k是0至6的任何整数,优选1至6的任何整数,更优选k = 6; b)式(II)的环状肽:环(Ala-xx-Trp-xx-Gly-x-Phe-x-Cys-xh-Gln),(II),其中h是0至2的任何整数, 1或2; c)式(III)的环肽:环(Ala-x-x-x-x-x-x-x-x-x-x-Pro-x-Cys-Cys-xi-Gln) (HI),其中j是0至4的任何整数,优选j = 4; 其中i是0至6的整数,优选1至6的任何整数,更优选i-6; 和d)式(IV)的肽:Ala-x1-Cys-xm-Cys-xxx-Pro-x-Cys-Cys-xn-Gln,(IV)其中1是0至9的任何整数, 1〜9的整数,更优选n = 9; 其中m是0至4的整数,优选1至4的任何整数,更优选m = 4; 其中n是0至6的整数,优选1至6的任何整数,更优选n = 6; 其中x是任何氨基酸,优选任何天然存在的氨基酸,更优选任何天然存在的L-氨基酸。

    Means for the inhibition of anti-β1-adrenergic receptor antibodies
    4.
    发明授权
    Means for the inhibition of anti-β1-adrenergic receptor antibodies 有权
    用于抑制抗β1肾上腺素能受体抗体的方法

    公开(公告)号:US08187605B2

    公开(公告)日:2012-05-29

    申请号:US11910258

    申请日:2006-03-31

    CPC分类号: C07K14/70571 C07K7/64

    摘要: Embodiments of the present invention provide for novel peptides of use for detection and/or inhibition of anti-β1-adrenergic receptor antibodies. Certain embodiments concern uses of cyclic and/or linear peptides. In other embodiments, the present invention relates to novel peptides of use in diagnostic and/or pharmaceutical compositions. Some embodiments concern diagnosing and/or treating cardiac conditions. Cardiac conditions of the instant invention can concern infectious heart disease, non-infectious heart disease, ischemic heart disease, non-ischemic heart disease, inflammatory heart disease, myocarditis, cardiac dilatation, idiopathic cardiomyopathy, idiopathic dilated cardiomyopathy, immune-cardiomyopathy, heart failure, and any cardiac arrhythmia condition.

    摘要翻译: 本发明的实施方案提供了用于检测和/或抑制抗 - 1-肾上腺素能受体抗体的新型肽。 某些实施方案涉及环肽和/或线性肽的使用。 在其它实施方案中,本发明涉及用于诊断和/或药物组合物的新型肽。 一些实施方案涉及诊断和/或治疗心脏病症。 本发明的心脏病可以涉及感染性心脏病,非传染性心脏病,缺血性心脏病,非缺血性心脏病,炎性心脏病,心肌炎,心脏扩张,特发性心肌病,特发性扩张型心肌病,免疫性心肌病,心力衰竭 ,以及任何心律失常症状。

    Mutant double cyclized receptor peptides inhibiting β1-adrenoceptor antibodies
    5.
    发明授权
    Mutant double cyclized receptor peptides inhibiting β1-adrenoceptor antibodies 有权
    突变双环化受体肽抑制和1-肾上腺素受体抗体

    公开(公告)号:US09062095B2

    公开(公告)日:2015-06-23

    申请号:US12733347

    申请日:2008-08-22

    摘要: The present invention relates to novel β-AR homologous cyclopeptide-mutants comprising only two cysteine residues able to form an intramolecular linkage, to linear peptides that can form these cyclopeptide-mutants and to nucleic acid molecules encoding these cyclopeptide-mutants and linear peptides. Moreover, vectors and recombinant host cells comprising said nucleic acid molecule and a method for producing the disclosed cyclopeptide-mutants are provided. Further provided is a composition comprising the peptides, nucleic acid molecules, vectors or host cells of the invention. The present invention also relates to therapeutic and diagnostic means, methods and uses taking advantage of the peptides of the invention and to means, methods and uses for detecting anti-β-adrenergic receptor antibodies like anti-β-adrenergic receptor antibodies.

    摘要翻译: 本发明涉及可以形成这些环肽突变体的线性肽和编码这些环肽突变体和线性肽的核酸分子的仅包含两个能够形成分子内连接的半胱氨酸残基的新颖的-b同源的环肽突变体。 此外,提供了包含所述核酸分子的载体和重组宿主细胞以及用于制备所公开的环肽突变体的方法。 还提供了包含本发明的肽,核酸分子,载体或宿主细胞的组合物。 本发明还涉及利用本发明的肽的治疗和诊断手段,方法和用途以及用于检测抗 - 抗 - 肾上腺素能受体抗体(如抗 - 肾上腺素能受体抗体)的手段,方法和用途。

    MUTANT DOUBLE CYCLIZED RECEPTOR PEPTIDES INHIBITING BETA1-ADRENOCEPTOR ANTIBODIES
    6.
    发明申请
    MUTANT DOUBLE CYCLIZED RECEPTOR PEPTIDES INHIBITING BETA1-ADRENOCEPTOR ANTIBODIES 有权
    突变型双循环受体肽抑制BETA-ADRENOCEPTOR抗体

    公开(公告)号:US20100209445A1

    公开(公告)日:2010-08-19

    申请号:US12733347

    申请日:2008-08-22

    摘要: The present invention relates to novel β-AR homologous cyclopeptide-mutants comprising only two cysteine residues able to form an intramolecular linkage, to linear peptides that can form these cyclopeptide-mutants and to nucleic acid molecules encoding these cyclopeptide-mutants and linear peptides. Moreover, vectors and recombinant host cells comprising said nucleic acid molecule and a method for producing the disclosed cyclopeptide-mutants are provided. Further provided is a composition comprising the peptides, nucleic acid molecules, vectors or host cells of the invention. The present invention also relates to therapeutic and diagnostic means, methods and uses taking advantage of the peptides of the invention and to means, methods and uses for detecting anti-β-adrenergic receptor antibodies like anti-βradrenergic receptor antibodies.

    摘要翻译: 本发明涉及可以形成这些环肽突变体的线性肽和编码这些环肽突变体和线性肽的核酸分子的仅包含两个能够形成分子内连接的半胱氨酸残基的新颖的-b同源的环肽突变体。 此外,提供了包含所述核酸分子的载体和重组宿主细胞以及用于制备所公开的环肽突变体的方法。 还提供了包含本发明的肽,核酸分子,载体或宿主细胞的组合物。 本发明还涉及利用本发明的肽的治疗和诊断手段,方法和用途以及用于检测抗 - 肾上腺素能受体抗体(如抗 - 肾上腺素能受体抗体)的手段,方法和用途。

    BINDING COMPOUNDS TO HUMAN Beta 1-ADRENORECEPTOR (Beta 1-AR) AND THEIR USE IN MEASUREMENT OF AUTO-ANTI- Beta 1-AR ANTIBODIES
    7.
    发明申请
    BINDING COMPOUNDS TO HUMAN Beta 1-ADRENORECEPTOR (Beta 1-AR) AND THEIR USE IN MEASUREMENT OF AUTO-ANTI- Beta 1-AR ANTIBODIES 审中-公开
    人β-ADRENORECEPTOR(Beta 1-AR)的结合化合物及其在自身抗体测定中的用途 - 1-AR抗体

    公开(公告)号:US20140273015A1

    公开(公告)日:2014-09-18

    申请号:US14124649

    申请日:2012-06-06

    IPC分类号: C07K16/28 G01N33/68 G01N33/74

    摘要: The present disclosure relates to binding compounds/antibodies that bind to the second extracellular loop of the human β1-adrenoreceptor (β1-AR-ECII) that are produced by/obtainable from a host cell/hybridoma with a deposit number selected from the group consisting of DSM ACC3121, DSM ACC3174, DSM ACC3175, DSM ACC3176 and DSM AC-C3177. The binding compounds/antibodies are particularly useful in determination of auto-anti-β1-AR antibodies in an in vitro cell based assay system in order to characterize and to identify auto-antibodies directed against the β1-AR-ECII in a biological sample. Further aspects of the disclosure are nucleic acid molecules encoding said binding compounds/antibodies, vectors, host cells, methods for producing the binding compounds/antibodies of the disclosure as well as a kit comprising the binding compounds/antibodies of the present disclosure.

    摘要翻译: 本公开涉及结合化合物/抗体,所述化合物/抗体结合由具有选择的保藏号的宿主细胞/杂交瘤产生/可获得的人β-肾上腺素受体(&bgr; 1-AR-ECII)的第二细胞外环 来自由DSM ACC3121,DSM ACC3174,DSM ACC3175,DSM ACC3176和DSM AC-C3177组成的组。 结合化合物/抗体特别可用于在基于体外​​细胞的测定系统中测定自身抗体和抗体1-AR抗体,以鉴定和鉴定针对1-AR-ECII的自身抗体 生物样品。 本公开的另外方面是编码所述结合化合物/抗体,载体,宿主细胞的核酸分子,用于产生本公开的结合化合物/抗体的方法以及包含本公开内容的结合化合物/抗体的试剂盒。